Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Source: View publication →
In patients with high-risk heart failure with reduced ejection fraction and a recent worsening event, the addition of the soluble guanylate cyclase stimulator vericiguat to standard therapy significantly reduced the composite risk of cardiovascular death or heart failure hospitalization.
Key Findings
Study Design
Study Limitations
Clinical Significance
The VICTORIA trial established vericiguat as a first-in-class therapeutic option for patients with high-risk HFrEF who experience worsening symptoms despite guideline-directed medical therapy. By specifically targeting the impaired NO-sGC-cGMP pathway, vericiguat addresses a distinct pathophysiological mechanism compared to conventional neurohormonal blockade. The results provided crucial evidence for incorporating sGC stimulators into the treatment paradigm for advanced, recently decompensated HFrEF patients, safely bridging a therapeutic gap for a population with an extremely high near-term morbidity and mortality risk.
Historical Context
Prior to the VICTORIA trial, standard heart failure therapies primarily focused on neurohormonal blockade (e.g., ACE inhibitors, ARBs, beta-blockers, MRAs, ARNIs, and SGLT2 inhibitors). However, the nitric oxide-soluble guanylate cyclase-cyclic GMP (NO-sGC-cGMP) pathway—which is impaired in heart failure due to endothelial dysfunction and oxidative stress—represented an untapped therapeutic target. Following the success of sGC stimulators like riociguat in pulmonary hypertension, the phase II SOCRATES-REDUCED trial evaluated the safety and target dosing for vericiguat. VICTORIA was uniquely designed to study a substantially higher-risk HFrEF population—specifically those with a recent worsening HF event—resulting in a much higher baseline event rate compared to contemporary landmark trials like PARADIGM-HF or DAPA-HF, thereby demonstrating the efficacy of targeting the NO-sGC-cGMP pathway in a highly vulnerable, decompensated cohort.
Guided Discussion
High-yield insights from every perspective
Vericiguat targets the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic GMP (cGMP) pathway. How does its mechanism of action differ from traditional nitrates used in heart failure or ischemic heart disease, and why might this be advantageous in a state of endothelial dysfunction?
Key Response
Nitrates require conversion to NO, and their efficacy is limited by tolerance and reduced NO bioavailability in endothelial dysfunction. Vericiguat directly stimulates sGC independent of NO and sensitizes it to endogenous NO, bypassing these limitations and restoring cGMP levels to improve myocardial and vascular function without causing nitrate tolerance.
The VICTORIA trial specifically enrolled patients with HFrEF who had a recent worsening event. Clinically, how do you define a worsening HF event, and how does this inclusion criterion influence your decision on when to initiate vericiguat in a patient's treatment timeline compared to foundational GDMT?
Key Response
A worsening event in VICTORIA was defined as a recent HF hospitalization or the need for outpatient IV diuretics. Residents must recognize that vericiguat is not first-line foundational GDMT; it is an add-on therapy specifically indicated for high-risk patients who continue to decompensate despite or while optimizing standard therapies like ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors.
The primary outcome in VICTORIA showed a modest absolute risk reduction, and subgroup analyses suggested diminished efficacy in patients with the highest quartiles of NT-proBNP. How should this potential 'sweet spot' of efficacy guide our deployment of vericiguat in the advanced heart failure clinic?
Key Response
Fellows should critically evaluate subgroup data. The data suggest vericiguat is effective after a decompensation but may lose efficacy in end-stage, severely remodeled, or highly decompensated HF (e.g., NT-proBNP > 8000 pg/mL). This highlights a specific therapeutic window before irreversible advanced HF sets in, where the NO-sGC pathway is still responsive to stimulation.
With the addition of vericiguat to the growing arsenal of HFrEF therapies, patients face substantial polypharmacy. How do you prioritize the introduction of vericiguat against titrating existing GDMT like ARNIs or SGLT2 inhibitors in a patient with borderline hemodynamics recovering from an acute exacerbation?
Key Response
Attendings must balance guidelines with real-world tolerability. Vericiguat is generally well-tolerated with only mild BP-lowering effects compared to ARNIs, but optimizing the core four pillars of GDMT (which have proven mortality benefits) generally takes precedence over adding a novel agent whose primary benefit is driven mostly by reduced hospitalizations.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The VICTORIA trial utilized an event-driven design with a remarkably high primary event rate in the placebo group due to the inclusion of recently decompensated patients. How does enriching a trial population for high baseline risk impact the statistical power, the required sample size, and the interpretation of absolute versus relative risk reduction?
Key Response
Enriching for high-risk patients allows a trial to reach the required number of events faster and with a smaller sample size, increasing statistical power. However, while the relative risk reduction (HR 0.90) might appear modest, the high baseline risk translates to a clinically meaningful absolute risk reduction, though it inherently limits the generalizability of the findings to more stable outpatients.
The primary endpoint in VICTORIA was a composite of cardiovascular death or heart failure hospitalization. As a peer reviewer, how would you scrutinize the individual components of this composite, particularly given the lack of a statistically significant reduction in cardiovascular mortality alone?
Key Response
Editors must ensure readers are not misled by composite endpoints. If CV death is not significantly reduced (HR 0.93, 95% CI 0.81-1.06), the manuscript must transparently state that the composite's success is driven primarily by hospitalizations. This impacts the perceived clinical value of the drug compared to foundational therapies that unequivocally improve survival.
Based on the VICTORIA trial results, what specific class of recommendation (COR) and level of evidence (LOE) should be assigned to vericiguat in the updated heart failure guidelines, and how does its positioning reflect its comparison against the foundational 'four pillars' of HFrEF therapy?
Key Response
In the 2022 AHA/ACC/HFSA HF guidelines, vericiguat received a Class 2b (LOE: B-R) recommendation. It may be considered to reduce HF hospitalizations and CV death in high-risk patients with HFrEF and recent worsening HF already on GDMT. The committee positioned it as a secondary, adjunctive option rather than replacing Class 1 recommendations due to its narrower inclusion criteria, lack of an independent mortality benefit, and modest relative risk reduction.
Clinical Landscape
Noteworthy Related Trials
PARADIGM-HF
Tested
Sacubitril/valsartan 200 mg twice daily
Population
Patients with symptomatic HFrEF (LVEF <= 40%)
Comparator
Enalapril 10 mg twice daily
Endpoint
Composite of CV death or heart failure hospitalization
DAPA-HF
Tested
Dapagliflozin 10 mg daily
Population
Patients with symptomatic HFrEF with or without type 2 diabetes
Comparator
Placebo
Endpoint
Composite of worsening heart failure or CV death
GALACTIC-HF
Tested
Omecamtiv mecarbil
Population
Patients with symptomatic HFrEF (LVEF <= 35%)
Comparator
Placebo
Endpoint
Composite of a heart failure event or CV death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis